Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kenneth Pennington"'
Autor:
Kenneth Pennington, Daniel J. Lee, Alberto J. Montero, Seza A. Gulec, Tanios Bekaii-Saab, David V. Gold, Allyson J. Ocean, David M. Goldenberg, William A. Wegener, Bert H. O'Neil, Arif Sheikh, Heather Horne, John S. Kauh, Michael Holt, Michael J. Guarino, Stanley J. Goldsmith, Max Sung, Aldo N. Serafini, Timothy Manzone, Nathan Hall
Publikováno v:
Cancer. 118:5497-5506
It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. After a trial of radioimmunotherapy that determined the maximum tolerated dose of single-dose yttrium-90-labeled hPA
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 38:1289-1295
Functional tumor volume (FTV) and total lesion glycolysis (TLG) are measures of metabolic activity of tumors determined by fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT images. These parameters could potentially have clinical value i
Autor:
Douglas J. Schwartzentruber, Michael Hall, Seza A. Gulec, James Wheeler, Tushar Barot, Kenneth Pennington, Rekha Suthar
Publikováno v:
American journal of clinical oncology. 36(5)
Selective internal radiation therapy (SIRT) with yttrium-90 (Y) microspheres has emerged as an effective liver-directed therapy with a favorable therapeutic ratio for treatment of colorectal cancer liver metastases. The aim of this study was to inves
Publikováno v:
American Journal of Clinical Oncology. 17:10-13
One potential explanation for why renal cell carcinoma is usually poorly responsive to chemotherapy is intrinsic multidrug resistance. Dipyridamole (DP) is one of several agents known to bind to P-glycoprotein and potentially reverse multidrug resist
Autor:
Gregory M. Springett, Edith P. Mitchell, Heather Horne, Allyson J. Ocean, David M. Goldenberg, William A. Wegener, Alberto J. Montero, John S. Kauh, Bekaii-saab Tanio, Max Sung, Kenneth Pennington, David V. Gold, Michael J. Guarino
Publikováno v:
Annals of Oncology. 23:iv5-iv6
Introduction Clivatuzumab (hPAM4) is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. Methods Fractionated radioimmunotherapy (RAIT) with 90Y-labeled humanized mAb (90Y-hPAM4) plus Gem as
Autor:
Tracy Thorne, Stew Kroll, Mohammed M. Milhem, Alexander Starodub, Ebenezer A. Kio, Barbara Hickingbottom, Daniel Bruetman, Kenneth Pennington
Publikováno v:
Journal of Clinical Oncology. 31:e15557-e15557
e15557 Background: Tumors often consist of highly hypoxic subregions known to be resistant to chemotherapy and radiotherapy. TH-302 is an investigational hypoxia-targeted drug with a 2-nitroimidazole trigger designed to release the DNA alkylator brom
Autor:
John S. Kauh, Seza A. Gulec, David V. Gold, Kenneth Pennington, Tanios Bekaii-Saab, Heather Horne, Michael J. Guarino, Edith P. Mitchell, Allyson J. Ocean, David M. Goldenberg, Gregory M. Springett, Alberto J. Montero, Max Sung, William A. Wegener
Publikováno v:
Journal of Clinical Oncology. 30:4043-4043
4043 Background: A Phase I/II trial evaluated single and repeated cycles of fractionated radioimmunotherapy (RAIT) with 90Y-labeled humanized mAb (90Y-hPAM4) plus Gem as first-line therapy in Stage 3-4 APC. Methods: Cycles of Gem once-weekly x 4 with
Autor:
William A. Wegener, Kenneth Pennington, Edith P. Mitchell, Allyson J. Ocean, David M. Goldenberg, David V. Gold, Gregory M. Springett, Alberto J. Montero, Seza A. Gulec, Tanios Bekaii-Saab, John S. Kauh, Max Sung, Heather Horne, Michael J. Guarino
Publikováno v:
Journal of Clinical Oncology. 30:227-227
227 Background: A Phase I/II trial was undertaken to evaluate repeated cycles of 90Y-labeled anti-mucin humanized mAb (90Y-hPAM4) plus Gem as first-line therapy in Stage 3-4 APC. Methods: Pts received Gem once-weekly x 4 with 90Y-hPAM4 on wks 2, 3 an
Autor:
William A. Wegener, Kenneth Pennington, Nick Teoh, Alberto J. Montero, Allyson J. Ocean, David V. Gold, David M. Goldenberg, Michael J. Guarino, Seza A. Gulec, Tanios Bekaii-Saab
Publikováno v:
Journal of Clinical Oncology. 29:240-240
240 Background: The90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), is in clinical development in APC. A phase I/II trial of 90Y-hPAM4 with low-dose radiosensitizing Gem has now concluded 90Y-dose escalation. Methods: Pts wi
Autor:
William A. Wegener, Michael J. Guarino, David V. Gold, Kenneth Pennington, C. S. Rocha Lima, Allyson J. Ocean, David M. Goldenberg, Bert H. O'Neil, Seza A. Gulec, Tanios Bekaii-Saab
Publikováno v:
Journal of Clinical Oncology. 28:4115-4115
4115 Background: Since a single dose of 90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), showed transient objective antitumor activity in APC, we are evaluating repeated t...